Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00827099 · OUTCOME

Number of Patients Who Survive Following Treatment on This Protocol

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer · Source last updated 2012-03-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Through Death

What was measured

Patients will be followed until death

Analysis population: This study was terminated early. No participants were analyzed.

Groups in this outcome

Umbilical Cord Blood Transplant

High dose conditioning with Fludarabine \& Melphalan

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Umbilical Cord Blood Transplant0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Patients will be followed until death
groups
  1. description
    High dose conditioning with Fludarabine \& Melphalan
    id
    OG000
    title
    Umbilical Cord Blood Transplant
param Type
NUMBER
population Description
This study was terminated early. No participants were analyzed.
reporting Status
POSTED
time Frame
Through Death
title
Number of Patients Who Survive Following Treatment on This Protocol
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice